Eagle Health Investments LP Grows Position in Guardant Health, Inc. $GH

Eagle Health Investments LP lifted its position in Guardant Health, Inc. (NASDAQ:GH) by 9.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 310,281 shares of the company’s stock after buying an additional 26,181 shares during the quarter. Guardant Health comprises approximately 5.0% of Eagle Health Investments LP’s holdings, making the stock its 4th largest position. Eagle Health Investments LP’s holdings in Guardant Health were worth $28,661,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. V Square Quantitative Management LLC acquired a new position in Guardant Health in the 4th quarter valued at $27,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Guardant Health during the fourth quarter valued at about $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health in the fourth quarter valued at about $35,000. Parallel Advisors LLC grew its position in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares during the last quarter. Finally, Ascentis Independent Advisors acquired a new stake in shares of Guardant Health in the first quarter valued at about $38,000. 92.60% of the stock is owned by institutional investors.

Insider Activity at Guardant Health

In related news, CEO Helmy Eltoukhy sold 100,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,012,919 shares of the company’s stock, valued at $254,231,669.70. This trade represents a 4.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Amirali Talasaz sold 143,028 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12. Following the completion of the transaction, the chief executive officer directly owned 1,881,336 shares of the company’s stock, valued at approximately $285,097,657.44. This trade represents a 7.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 708,565 shares of company stock worth $90,556,597 in the last three months. Company insiders own 5.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GH. Morgan Stanley boosted their price objective on Guardant Health from $130.00 to $175.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Wolfe Research started coverage on Guardant Health in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price target on the stock. Canaccord Genuity Group increased their price objective on Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. TD Cowen restated a “buy” rating on shares of Guardant Health in a research note on Thursday, July 2nd. Finally, Evercore reaffirmed an “outperform” rating and set a $200.00 target price on shares of Guardant Health in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $160.04.

Guardant Health Stock Down 1.3%

Shares of GH opened at $145.47 on Tuesday. The stock’s 50-day moving average price is $140.40 and its 200 day moving average price is $112.25. The firm has a market capitalization of $19.29 billion, a price-to-earnings ratio of -42.91 and a beta of 1.59. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $174.08.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.